We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response | Less Is More

The Lariat for Left Atrial Appendage Closure: Rehash of Known Literature or a True Analysis?

Hosakote Nagaraj, MD1; David Wilber, MD2; Dhanunjaya R. Lakkireddy, MD3
[+] Author Affiliations
1Nebraska Heart Institute, Lincoln
2Division of Cardiovascular Medicine, Loyola University Medical Center, Chicago, Illinois
3Cardiovascular Research Institute, University of Kansas Hospital, Kansas City
JAMA Intern Med. 2015;175(11):1867-1868. doi:10.1001/jamainternmed.2015.5386.
Text Size: A A A
Published online


To the Editor We read with great interest the recent review of a small body of literature in JAMA Internal Medicine by Chatterjee et al.1

The implication by Chatterjee et al that somehow the US Food and Drug Administration (FDA) was lax in their approval of 510(k) class II status for the Lariat snare device (SentreHeart Inc) is perplexing. It is not unusual for device manufacturers to obtain marketing authorization for one use and then seek additional indications for a different use based on clinical need. Clinical scenarios often force physicians to make choices using clinical tools based on medical necessity. Those of us who have seen devastating bleeding complications from oral anticoagulation or strokes from failed anticoagulation strategies have chosen to close the left atrial appendage (LAA) with a device that is capable of doing the job with a high rate of complete closure.2 Many patients we have ligated with a Lariat had no choice other than open heart surgery or to stop their anticoagulation, which would leave them vulnerable to an atrial fibrillation (AF)-related stroke. Most cases where the Lariat is used off-label are “compassionate” cases that have no other FDA-approved alternative.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





November 1, 2015
Mukta C. Srivastava, MD; Vincent Y. See, MD
1Division of Cardiovascular Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore
JAMA Intern Med. 2015;175(11):1868-1869. doi:10.1001/jamainternmed.2015.5399.
November 1, 2015
Saurav Chatterjee, MD; Jay Giri, MD, MPH
1Division of Cardiology, St Luke’s-Roosevelt Hospital, Mount Sinai Health System, New York, New York
2Cardiovascular Medicine Division, University of Pennsylvania Perelman School of Medicine, Philadelphia
JAMA Intern Med. 2015;175(11):1869-1870. doi:10.1001/jamainternmed.2015.5405.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...